News

Our very own Dr. Heiland has been featured on BioBuzz.  Click below to read the full Q&A Interview, as Dr. Heiland discusses our technology platform name change to UNITE and

Scientific American custom media and Immunomic Therapeutics, Inc. wrote this article titled, “After the Gold Rush." Immuno-oncology (IO) has seen a flood of advancements, investment deals and partnerships, but the

Scientific American custom media and Immunomic Therapeutics released an article titled, “The Fight Against Cancer is Increasingly Personal,” by reclassifying tumors, scientists are finding a path to genuine cancer cures.

Immuno-Oncology Panel led by Scientific American February 12, 2018 07:30 AM Eastern Standard Time   ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics (ITI), pioneering the study of investigational LAMP-based nucleic acid immunotherapy programs,

January 23, 2018 11:24 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Tomorrow, Immunomic Therapeutics, Inc. Senior Director of Corporate Development Sia Anagnostou will present at Phacilitate’s Immuno-Oncology Frontiers World in Miami.

Presentation to Examine the Potential of LAMP Enhancing Antitumor Immunity November 13, 2017 07:30 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Tomorrow, Immunomic Therapeutics, Inc. scientist, Dr. Pratima Sinha, will present

Sia Anagnostou, Senior Director at Immunomic Therapeutics authored this article, "Md. is developing the next generation of life-saving vaccines" in the Baltimore Sun. http://www.baltimoresun.com/news/opinion/oped/bs-ed-op-1020-vaccines-md-20171018-story.html  

Immunomic Therapeutics, a biotechnology company developing a new type of vaccine based on Johns Hopkins research, has reached a $300 million deal licensing its technology to Japanese company Astellas Pharma.

Allergy treatments enter a new era — with a focus on stopping reactions before they start MEGHANA KESHAVAN @megkesh NOVEMBER 29, 2016 Allergy treatments haven’t advanced much in decades, even

The Washington Business Journal article tells the story of the evolution of Immunomic Therapeutics and its strategy in applying LAMP-Vax in dierent disease areas. The article further highlights Immunomics partnering